Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249598 | 0.86 | ALDH1A1 (0.37) | CA2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL22793065 | 0.79 | CA2 (0.35) | CA2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL20689814 | 0.76 | QPCT (0.46) | CA2ALDH1A1GAATSHRTDP1 | |
| SCHEMBL13249599 | 0.76 | QPCT (0.43) | ALDH1A1KDM4EGAAHPGDKLK7 | |
| SCHEMBL24979192 | 0.70 | CA2 (0.35) | CA2ALDH1A1TSHRTDP1GABRA1 | |
| SCHEMBL13431385 | 0.70 | MAP4K4 (0.37) | CA2ALDH1A1GAATSHRTDP1 | |
| SCHEMBL6370683 | 0.70 | NUDT1 (0.42) | CA2ALDH1A1KDM4EGAATSHR | |
| SCHEMBL14963064 | 0.70 | ALDH1A1 (0.34) | CA2ALDH1A1TSHRTDP1MAPT | |
| SCHEMBL4569219 | 0.70 | MAP4K4 (0.41) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL22792911 | 0.69 | ALDH1A1 (0.39) | CA2ALDH1A1KDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220401430-A1 | ALLOSTERIC MODULATORS OF THE MU OPIOID RECEPTOR | Chiromics, LLC | 2022-12-22 | — | — | US | disclosed |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | Chiromics, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-10894038-B2 | Indolizine derivatives, composition and methods of use | SHANGHAI FOCHON PHARMACEUTICAL CO. LTD. (CN) | 2021-01-19 | — | — | US | disclosed |
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | Chiromics, LLC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200113876-A1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | FOCHON PHARMACEUTICALS, LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| US-10603313-B2 | Allosteric modulators of the mu opioid receptor | Chiromics, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190030020-A1 | Allosteric Modulators of the Mu Opioid Receptor | Chiromics, LLC (US) | 2019-01-31 | — | — | US | disclosed |
| US-9844539-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | disclosed |
| US-9469640-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160168146-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-06-16 | — | — | US | disclosed |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140038948-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130237531-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-09-12 | — | — | US | disclosed |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603313-B2 | Allosteric modulators of the mu opioid receptor | OPRM1, OPRK1, OPRD1 | CA2 4608/4885ALDH1A1 2533/4885KDM4E 630/4885 |
| US-20160168146-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885ALDH1A1 4348/4885KDM4E 2029/4885 |
| US-20220401430-A1 | ALLOSTERIC MODULATORS OF THE MU OPIOID RECEPTOR | OPRM1, OPRK1, OPRD1 | CA2 4608/4885ALDH1A1 2533/4885KDM4E 630/4885 |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | CA2 94/4885ALDH1A1 2001/4885KDM4E 4592/4885 |
| US-20130237531-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885ALDH1A1 4348/4885KDM4E 2029/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CA2 4029/4885ALDH1A1 312/4885KDM4E 2437/4885 |
| US-20200113876-A1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | INMT, SLC14A1, AADAT | CA2 2893/4885ALDH1A1 745/4885KDM4E 3374/4885 |
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | OPRM1, OPRK1, OPRD1 | CA2 4608/4885ALDH1A1 2533/4885KDM4E 630/4885 |
| US-10894038-B2 | Indolizine derivatives, composition and methods of use | INMT, SLC14A1, AADAT | CA2 2893/4885ALDH1A1 745/4885KDM4E 3374/4885 |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885ALDH1A1 4348/4885KDM4E 2029/4885 |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K11, MAP3K10 | CA2 3771/4885ALDH1A1 3137/4885KDM4E 2057/4885 |
| US-20190030020-A1 | Allosteric Modulators of the Mu Opioid Receptor | OPRM1, OPRK1, OPRD1 | CA2 3645/4885ALDH1A1 3558/4885KDM4E 1146/4885 |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885ALDH1A1 4348/4885KDM4E 2029/4885 |
| US-20140038948-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885ALDH1A1 4348/4885KDM4E 2029/4885 |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CA2 3958/4885ALDH1A1 4348/4885KDM4E 2029/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CA2 4029/4885ALDH1A1 312/4885KDM4E 2437/4885 |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | OPRM1, OPRK1, OPRD1 | CA2 4608/4885ALDH1A1 2533/4885KDM4E 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.